Navigating The Pending BIOSECURE Act: Implications For U.S.-China Biopharmaceutical Collaboration And National Security - New Technology
The BIOSECURE Act (H.R. 7085), which has the potential to severely restrict the ability of U.S. biopharmaceutical companies to collaborate with certain Chinese entities without losing the ability to contract with the U.S. government, has made headlines in recent weeks.